DVYSR: Devyser Diagnostics AB (publ) - Summary | Jitta

Devyser Diagnostics AB (publ)

SWE:DVYSR

Price
kr96.50
Loss Chance
49.2%
4.48JITTA SCORE
371.58%Over Jitta Line
Jitta Ranking
14 / 107
140 / 616
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (63)
Recent Business Performance (86)
Financial Strength (52)
Return to Shareholders (1)
Competitive Advantage (57)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2025
Operating MarginInconsistent
CapExVery High
Key Stats
Jitta Score
Jitta Line
4.48
371.58%
2.24
119.80%
2.89
152.39%
Biotechnology
2.69
100.00%
2.77
100.00%
6.92
400.08%
COMPANY DESCRIPTION
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the interpretation of test results. The company was incorporated in 2004 and is headquartered in Årsta, Sweden.